ATTENTION PRCT Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

Core Insights - PROCEPT BioRobotics Corporation is under investigation for potential violations of federal securities laws, as announced by Levi & Korsinsky [1] Financial Performance - In Q3 2025 earnings call, the CFO reaffirmed a revenue target of $325.5 million and maintained average selling prices for handpieces at approximately $3,200 [2] - The company implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which directly reduced realized average selling prices on its core product line [2] - Actual revenue for Q4 2025 fell short by $17.4 million compared to the guidance, and FY 2026 guidance of $410 million to $430 million was below analyst consensus, leading to a 15% drop in stock value in a single session [3]